Search research articles
Contact Us
Filters
Showing results (31-40 of 37) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 37 results.
JCI Insight
|
August 24, 2018
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
Anshuman Panda, Aguirre A de Cubas, Mark Stein, et al.
Oncogene
|
August 28, 2021
SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis
Kevin Tong, Om A Kothari, Katherine S Haro, et al.
Scientific Reports
|
July 19, 2017
Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma
Sunniva Stordal Bjørklund, Anshuman Panda, Surendra Kumar, et al.
JCO Precision Oncology
|
June 29, 2018
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors
Anshuman Panda, Anil Betigeri, Kalyanasundaram Subramanian, et al.
The Journal of Clinical Investigation
|
May 10, 2016
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M Mehnert, Anshuman Panda, Hua Zhong, et al.
The Journal of Clinical Investigation
|
August 24, 2018
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
Christof C Smith, Kathryn E Beckermann, Dante S Bortone, et al.
Journal of the National Cancer Institute
|
November 21, 2017
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda, Janice M Mehnert, Kim M Hirshfield, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 37) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 37 results.
JCI Insight
|
August 24, 2018
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
Anshuman Panda, Aguirre A de Cubas, Mark Stein, et al.
Oncogene
|
August 28, 2021
SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis
Kevin Tong, Om A Kothari, Katherine S Haro, et al.
Scientific Reports
|
July 19, 2017
Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma
Sunniva Stordal Bjørklund, Anshuman Panda, Surendra Kumar, et al.
JCO Precision Oncology
|
June 29, 2018
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors
Anshuman Panda, Anil Betigeri, Kalyanasundaram Subramanian, et al.
The Journal of Clinical Investigation
|
May 10, 2016
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M Mehnert, Anshuman Panda, Hua Zhong, et al.
The Journal of Clinical Investigation
|
August 24, 2018
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
Christof C Smith, Kathryn E Beckermann, Dante S Bortone, et al.
Journal of the National Cancer Institute
|
November 21, 2017
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda, Janice M Mehnert, Kim M Hirshfield, et al.
Page
of 4